Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,874 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pulmonary Disease Clear all
Active, not recruiting Phase 1 Interventional

Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer

NCT00264602
View directory record Official record
Conditions
Lung Cancer
Interventions
Near Infrared Imaging
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2029
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 23, 2026, 4:46 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT05355701
View directory record Official record
Conditions
Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions
PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
31
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Not applicable Interventional Results available

Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)

NCT00958919
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
naloxone, normal saline
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 23, 2026, 4:46 PM EDT
Completed No phase listed Observational

Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)

NCT02684422
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Cystic Fibrosis
Interventions
Intervention N/A. Observational study
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors

NCT00413322
View directory record Official record
Conditions
Tumor
Interventions
belinostat, 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 23, 2026, 4:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

NCT06188702
View directory record Official record
Conditions
MTAP-deleted Solid Tumors
Interventions
S095035, TNG462
Drug
Lead sponsor
Servier Bio-Innovation LLC
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Lake Mary, Florida • Indianapolis, Indiana • Maumee, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Not applicable Interventional

Dexmedetomidine Infusion and Postoperative Lung Aeration After Thoracic Surgery

NCT06502002
View directory record Official record
Conditions
Surgery-Complications, Respiratory Complication, Lung Injury, Acute
Interventions
Dexmedetomidine Hydrochloride, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 23, 2026, 4:46 PM EDT
Not yet recruiting Phase 2 Interventional

Ginger's Therapeutic Potential in Asthma

NCT07792395
View directory record Official record
Conditions
Asthma
Interventions
Ginger Extract, Placebo
Drug
Lead sponsor
Emily DiMango, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Terminated Phase 1 Interventional

A Study of PY314 in Subjects With Advanced Solid Tumors

NCT04691375
View directory record Official record
Conditions
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Lung Adenocarcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, Ovarian Cancer
Interventions
PY314, Combination Therapy: PY314 + Pembrolizumab
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 23, 2026, 4:46 PM EDT
Not listed Phase 1 Interventional

Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer

NCT04052412
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
18F-AraG
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 23, 2026, 4:46 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

NCT05121428
View directory record Official record
Conditions
Opioid-use Disorder, Acceptability of Health Care, Opioid-Related Disorders
Interventions
Not listed
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

NCT03538028
View directory record Official record
Conditions
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer, Hepatocellular Carcinoma, Melanoma (Uveal Melanoma Excluded), Merkel Cell Carcinoma, Mesothelioma, MSI-high Colorectal Cancer, Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), Triple-negative Breast Cancer, Urothelial Carcinoma, Diffuse Large B-cell Lymphoma
Interventions
INCAGN02385
Biological
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 23, 2026, 4:46 PM EDT
Terminated Not applicable Interventional

Noninvasive Estimation of Work of Breathing

NCT02867228
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
changes in ventilator settings
Other
Lead sponsor
Respironics, California, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 1Phase 2 Interventional

Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation

NCT00029328
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Bronchiolitis Obliterans, Pneumonia
Interventions
etanercept
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
12 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 23, 2026, 4:46 PM EDT
Terminated Phase 2 Interventional Results available

Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease

NCT00532883
View directory record Official record
Conditions
Hemoglobin SC Disease
Interventions
Hydroxyurea, Magnesium Pidolate, Placebo Pills and Placebo Liquid
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 23, 2026, 4:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Ganetespib in Combination With Doxorubicin

NCT02261805
View directory record Official record
Conditions
Cancer, Small Cell Lung Cancer
Interventions
Ganetespib, Doxorubicin
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 23, 2026, 4:46 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

KIDney Injury in Times of COVID-19 (KIDCOV)

NCT04705766
View directory record Official record
Conditions
SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury, Kidney Injury
Interventions
Urine Collection
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms

NCT01064466
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
ETOPOSIDE - Usual, ETOPOSIDE - Study
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair
Industry
Eligibility
24 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Active, not recruiting Phase 2 Interventional

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation

NCT04476953
View directory record Official record
Conditions
Covid19
Interventions
Placebo, Fisetin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 23, 2026, 4:46 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

NCT05199272
View directory record Official record
Conditions
Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Neuroendocrine Tumors, MSI-H Cancer, Cancer With A High Tumor Mutational Burden, Extensive-stage Small-cell Lung Cancer
Interventions
23ME-00610
Drug
Lead sponsor
23andMe, Inc.
Industry
Eligibility
12 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Palo Alto, California • Atlanta, Georgia • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 4 Interventional Results available

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

NCT02677701
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo (for azithromycin), inhaled tobramycin
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
12 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 23, 2026, 4:46 PM EDT
Active, not recruiting No phase listed Interventional

Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

NCT00499330
View directory record Official record
Conditions
Lung Cancer
Interventions
lobectomy, segmentectomy or wedge resection
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
373
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 245 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00671073
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Oglemilast, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
40 Years to 80 Years
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 23, 2026, 4:46 PM EDT
Completed Phase 4 Interventional Results available

Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.

NCT01323673
View directory record Official record
Conditions
Dermatitis, Chronic
Interventions
clobetasol propionate 0.05%, Vehicle / Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
San Diego, California • Boynton Beach, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 23, 2026, 4:46 PM EDT